Dutkowski P, Kneist W, Sultanow F, Junginger Th
Klinik für Allgemein- und Abdominalchirurgie, Universität Mainz, Langenbeckstrasse 1, 55101 Mainz.
Kongressbd Dtsch Ges Chir Kongr. 2002;119:333-8.
A retrospective analysis should compare the two operative approaches, transhiatal or transthoracic resection in patients suffering from adenocarcinoma of the esophagus. Between 1985 and 2002 123 cases were presented with adenocarcinoma of the esophagus, treated in 65% by transhiatal resection including abdominal lymph node dissection and in 35% by the transthoracic approach with standardized extended mediastinal and abdominal lymph node dissection. Hospital mortality was 14% (6/43) after transthoracic resection and 3.8% (3/80) after transhiatal resection (ns). Die number of removed and examined abdominal lymph nodes following transhiatal resection was 14.1 (mean) versus 12.3 (mean) after transthoracic resection (ns). Die number of removed and examined mediastinal lymph nodes by transhiatal resection was 6.3 (mean) versus 19.7(mean) after transthoracic resection (p < 0.001). The median survival after transthoracic approach was 19 months versus 20 months after transhiatal approach (ns). Median survival of curatively resected patients (R0) were in both operative procedures similar (21 months). A more differentiated analysis referred to the UICC stages also demonstrated no differences in the survival between transthoracic and transhiatal resection. With respect to less mortality and less morbidity after transhiatal resection and because of the not detectable prognostic advantage of the transthoracic resection we suggest the transhiatal approach as the treatment of choice in patients with adenocarcinoma of the esophagus.
一项回顾性分析应对患有食管腺癌的患者的两种手术方法,即经裂孔或经胸切除术进行比较。1985年至2002年间,共123例食管腺癌患者,其中65%接受经裂孔切除术,包括腹部淋巴结清扫;35%接受经胸手术,进行标准化的扩大纵隔和腹部淋巴结清扫。经胸切除术后医院死亡率为14%(6/43),经裂孔切除术后为3.8%(3/80)(无显著性差异)。经裂孔切除术后切除并检查的腹部淋巴结平均数为14.1个,经胸切除术后为12.3个(无显著性差异)。经裂孔切除术后切除并检查的纵隔淋巴结平均数为6.3个,经胸切除术后为19.7个(p<0.001)。经胸手术的中位生存期为19个月,经裂孔手术为20个月(无显著性差异)。两种手术方式中,根治性切除患者(R0)的中位生存期相似(21个月)。一项针对国际抗癌联盟(UICC)分期的更具差异性的分析也表明,经胸和经裂孔切除术在生存率方面无差异。鉴于经裂孔切除术后死亡率和发病率较低,且经胸切除术未显示出可检测到的预后优势,我们建议将经裂孔手术作为食管腺癌患者的首选治疗方法。